Nov 24,2020 09:27 AM
Biocon rose 0.80% to Rs 423.25 after the company announced the acquisition of 26% stake in Hinduja Renewables Two (HRTPL).
|Resolution Type||Description Of Resolution||IiAS Recommendation|
|Name||LTP||PE||Mar Cap||NP Qtr||Div. Yld||Sales Qtr||BV|
|Sun Pharmaceuticals Industries Ltd||520.15||43.29||124,741.43||724.81||0.77||3,207.24||106.10|
|Divis Laboratories Ltd||3,537.05||53.44||93,958.62||513.30||0.45||1,713.78||313.47|
|Dr Reddys Laboratories Ltd||4,915.50||33.25||81,661.83||481.00||0.51||3,333.60||979.45|
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Biocon Limited is Indias largest and fully-integrated, innovation-led biopharmaceutical company. Some of its key brands are INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab), KRABEVAA (Bevacizumab) and ALZUMAb (Itolizumab), a first in class anti-CD6 monoclonal antibody. The company has a rich pipeline of Biosimilars and Novel Biologics at various stages of development including Insulin Tregopil, ... More
Reports by biocon
Nov 25, 2020 02:06 AM
The company’s consolidated revenue stood at Rs1,540.80cr, up 45.65% yoy and 16.64% qoq.
22 Oct 2020
06 Oct 2020
BIOCON LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled o... More
22 Sep 2020
22 Sep 2020
With reference to the captioned subject, pursuant to Regulation 30 of SEBI Listing Regulations, we w... More
24 Jul 2020
01 Jul 2020
AGM 23/07/2020Newspaper Advertisement - Notice - 42nd Annual General Meeting of Biocon Limited to be... More